HighTower Advisors LLC Has $1.65 Million Position in Guardant Health, Inc. (NASDAQ:GH)

HighTower Advisors LLC cut its holdings in Guardant Health, Inc. (NASDAQ:GH – Get Rating) by 6.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,730 shares of the company’s stock after selling 4,422 shares during the quarter. HighTower Advisors LLC owned about 0.06% of Guardant Health worth $1,648,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Captrust Financial Advisors raised its stake in shares of Guardant Health by 33.2% in the 2nd quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock valued at $44,000 after acquiring an additional 271 shares in the last quarter. Manchester Capital Management LLC grew its stake in Guardant Health by 43.0% in the 3rd quarter. Manchester Capital Management LLC now owns 965 shares of the company’s stock valued at $52,000 after buying an additional 290 shares during the last quarter. Baird Financial Group Inc. grew its stake in Guardant Health by 2.1% in the 3rd quarter. Baird Financial Group Inc. now owns 14,580 shares of the company’s stock valued at $785,000 after buying an additional 296 shares during the last quarter. Amalgamated Bank raised its holdings in Guardant Health by 1.8% in the 3rd quarter. Amalgamated Bank now owns 22,164 shares of the company’s stock worth $1,193,000 after acquiring an additional 385 shares during the period. Finally, Public Employees Retirement System of Ohio lifted its position in Guardant Health by 0.8% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 48,907 shares of the company’s stock worth $2,633,000 after acquiring an additional 385 shares during the last quarter. 90.43% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GH has been the topic of a number of recent analyst reports. UBS Group started coverage on Guardant Health in a research report on Friday, May 5th. They set a “buy” rating and a $40.00 price objective for the company. Morgan Stanley reduced their price objective on Guardant Health from $73.00 to $66.00 and set an “overweight” rating for the company in a research report on Monday, February 27th. Credit Suisse Group dropped their target price on shares of Guardant Health from $60.00 to $55.00 in a research report on Wednesday, May 10th. Cowen reduced their price target on shares of Guardant Health from $70.00 to $53.00 and set an “outperform” rating for the company in a report on Friday, February 24th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Guardant Health from $75.00 to $65.00 and set an “overweight” rating on the stock in a report on Friday, February 24th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $55.80.

Insiders Place Their Bets

In other Guardant Health news, CEO Helmy Eltoukhy acquired 8,600 shares of the business’s stock in a transaction on Wednesday, March 15th. The stock was purchased at an average price of $26.15 per share, for a total transaction of $224,890.00. Following the transaction, the chief executive officer now owns 2,049,238 shares in the company, valued at approximately $53,587,573.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Helmy Eltoukhy acquired 8,600 shares of the stock in a transaction on Wednesday, March 15th. The stock was purchased at an average price of $26.15 per share, for a total transaction of $224,890.00. Following the transaction, the chief executive officer now owns 2,049,238 shares of the company’s stock, valued at approximately $53,587,573.70. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Amirali Talasaz bought 40,000 shares of Guardant Health stock in a transaction dated Monday, March 13th. The shares were bought at an average price of $25.66 per share, for a total transaction of $1,026,400.00. Following the completion of the transaction, the chief executive officer now directly owns 1,893,845 shares of the company’s stock, valued at approximately $48,596,062.70. The disclosure for this purchase can be found here. Insiders own 5.90% of the company’s stock.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $27.87 on Friday. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -4.29 and a beta of 0.82. The business’s fifty day moving average price is $24.98 and its two-hundred day moving average price is $31.61. Guardant Health, Inc. has a fifty-two week low of $20.67 and a fifty-two week high of $62.75. The company has a debt-to-equity ratio of 18.90, a current ratio of 5.41 and a quick ratio of 5.18.

Guardant Health (NASDAQ:GH – Get Rating) last announced its earnings results on Thursday, February 23rd. The company reported ($1.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.04. The business had revenue of $126.89 million during the quarter, compared to analysts’ expectations of $125.43 million. Guardant Health had a negative net margin of 137.90% and a negative return on equity of 530.36%. As a group, analysts predict that Guardant Health, Inc. will post -4.73 EPS for the current fiscal year.

Guardant Health Company Profile

(Get Rating)

Guardant Health, Inc is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.